1. Home
  2. SST vs APRE Comparison

SST vs APRE Comparison

Compare SST & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo System1 Inc.

SST

System1 Inc.

HOLD

Current Price

$2.07

Market Cap

12.9M

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

N/A

Current Price

$0.67

Market Cap

11.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SST
APRE
Founded
2013
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
11.5M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
SST
APRE
Price
$2.07
$0.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$10.00
$4.10
AVG Volume (30 Days)
233.3K
42.7K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.22
EPS
N/A
N/A
Revenue
$266,129,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.35
$0.55
52 Week High
$9.30
$1.70

Technical Indicators

Market Signals
Indicator
SST
APRE
Relative Strength Index (RSI) 50.75 49.72
Support Level $1.46 $0.58
Resistance Level $2.09 $0.79
Average True Range (ATR) 0.26 0.05
MACD 0.07 0.01
Stochastic Oscillator 40.25 42.07

Price Performance

Historical Comparison
SST
APRE

About SST System1 Inc.

System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It operate several flagship brands across multiple consumer verticals, including shopping, travel and search, and a customer acquisition and marketing platform powered by Artificial Intelligence and machine learning. The company's segment includes Marketing and Products. It generates maximum revenue from the Marketing segment. Geographically, it operates in United States and Other countries.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: